Comparison of percutaneous radiofrequency ablation and CyberKnife® for initial solitary hepatocellular carcinoma: A pilot study

Figure 4 Clinical example of patient had late adverse events by CyberKnife^®. A 66-year old male with hepatitis B virus cirrhosis received CyberKnife^® therapy at a dose of 42 Gy in 3 fractions for hepatocellular carcinoma sized 40 mm in diameter in S4. The Child-Pugh score before the treatment was 7 and the score rose with 13 when 12 mo after the treatment. After he died of liver failure. A: Dynamic computed tomography (CT) scan in arterial phase before the treatment showed a hypervascular lesion in S4 (arrow); B: The lesion was showed as a hypovasclular lesion on dynamic CT scan in arterial phase 12 mo after the treatment (arrow), but dynamic CT scan showed liver atrophy and massive ascites.